Interestingly, NSCLC patients with HER2 mutations tend to exhibit a more aggressive disease phenotype with increased incidence of brain metastases during treatment; this association is significantly higher in individuals harboring the exon 20 A775_G776insYVMA insertion compared to non-YVMA cases [8,9]. Here, ERBB2 is linked to non-small cell lung carcinoma.